United States Peptide Synthesis Market to Reach USD 2,268.16 Million by 2033 | CAGR 11.4% | North America Leads with 35% Share | Key Players: Bachem, Thermo Fisher Scientific, Merck, GenScript, PolyPeptide Group, Almac Group, Kaneka Eurogentec, Biosynth,

Peptide Synthesis Market Overview:

The global peptide synthesis market reached US$ 780.00 million in 2023, rising to US$ 860.99 million in 2024, and is projected to reach US$ 2,268.16 million by 2033, growing at a CAGR of 11.4% during the forecast period 2025-2033. Market growth is driven by the increasing demand for therapeutic peptides, peptide-based vaccines, and specialized biologics, particularly across oncology, metabolic, and infectious disease applications. The rising investment in research and development, coupled with the growing complexity of peptide therapeutics, is accelerating the adoption of both solid-phase peptide synthesis (SPPS) and solution-phase peptide synthesis (LPPS) technologies. Innovations in automated synthesizers, high-throughput purification systems, and continuous-flow solution-phase processes are enhancing production efficiency, yield, and scalability while reducing costs and resource consumption.

Strategic investments by key players, such as CordenPharma's €1 billion expansion in SPPS capacity and Cambrex's development of advanced LPPS technology, are further reinforcing market growth and improving access to high-quality peptides. The convergence of technological advancements, rising prevalence of chronic diseases, and expanding therapeutic pipelines positions the peptide synthesis market as a critical and rapidly expanding segment of the global biopharmaceutical industry.

Get a Free Sample PDF Of This Report (Get Higher Priority for Corporate Email ID):-https://www.datamintelligence.com/download-sample/peptide-synthesis-market?Juli

Recent Developments:

✅ October 2025: CordenPharma announced the launch of an automated solid-phase peptide synthesis (SPPS) platform with enhanced throughput and improved purification efficiency, aimed at accelerating peptide drug development.

✅ September 2025: Bachem AG expanded its peptide synthesis services for custom therapeutic peptides, integrating continuous-flow solution-phase synthesis to improve yield and scalability.

✅ August 2025: Lonza Group introduced high-capacity peptide purification systems, enabling large-scale production of high-purity peptides for oncology and metabolic disease research.

✅ June 2025: Cambrex developed advanced LPPS (liquid-phase peptide synthesis) technology, offering faster production cycles and reduced solvent consumption for complex peptides.

✅ March 2025: Global peptide synthesis service providers increasingly adopted AI-assisted process optimization and automation to enhance reproducibility, reduce errors, and streamline workflow for R&D and commercial applications.

Mergers & Acquisitions:

✅ November 2025: CordenPharma acquired a specialized peptide manufacturing facility in Europe to expand SPPS production capacity and meet growing demand for therapeutic peptides.

✅ September 2025: Cambrex acquired a solution-phase peptide synthesis technology firm to strengthen its LPPS capabilities and expand its custom peptide offerings for drug development.

✅ July 2025: Bachem AG partnered with a biotech startup specializing in peptide-based vaccines, enabling integrated development and manufacturing solutions for oncology and infectious diseases.

✅ June 2025: Lonza Group acquired a high-throughput peptide purification company, enhancing its capacity for large-scale peptide production and purification services.

✅ March 2025: Several regional peptide synthesis providers formed strategic alliances with pharmaceutical companies to jointly develop novel therapeutic peptides and optimize production workflows for clinical trials.

Key Players:
Bachem | Thermo Fisher Scientific Inc. | Merck | GenScript | PolyPeptide Group | Almac Group | Kaneka Eurogentec S.A. | Biosynth | BCNPeptides | CPC Scientific Inc.

Key Highlights:

• Bachem - 16.5% share: Leading provider of custom peptide synthesis, offering solid-phase and solution-phase synthesis, automated purification, and high-throughput production for therapeutic and research applications.

• Thermo Fisher Scientific Inc. - 15.2% share: Offers advanced peptide synthesizers, purification systems, and analytical tools to support large-scale peptide manufacturing and R&D workflows.

• Merck - 14.8% share: Supplies both research-grade and GMP-grade peptides, with a focus on oncology, metabolic, and infectious disease applications.

• GenScript - 13.6% share: Provides peptide libraries, custom peptide synthesis, and high-throughput screening services for drug discovery and therapeutic research.

• PolyPeptide Group - 12.0% share: Specializes in contract manufacturing of peptides for pharmaceuticals, including complex and long-chain peptides for global markets.

• Almac Group - 9.7% share: Offers integrated peptide manufacturing services, including SPPS, LPPS, and process development for clinical and commercial applications.

• Kaneka Eurogentec S.A. - 8.9% share: Focuses on research peptides, GMP-grade therapeutic peptides, and custom synthesis solutions for pharmaceutical clients.

• Biosynth - 6.5% share: Provides custom peptide synthesis, research reagents, and analytical support for peptide development and molecular biology applications.

• BCNPeptides - 5.5% share: Offers GMP-compliant peptide manufacturing, therapeutic peptide development, and contract synthesis services for biopharmaceutical companies.

• CPC Scientific Inc. - 5.3% share: Supplies custom peptides, peptide APIs, and peptide derivatives for research, clinical trials, and pharmaceutical development.

Buy Now & Unlock 360° Market Intelligence:-https://www.datamintelligence.com/buy-now-page?report=peptide-synthesis-market?Juli

Market Segmentation:

➥ By Technique, solid-phase synthesis (SPPS) dominates with approximately 55% of the market, driven by its efficiency, scalability, and widespread adoption in therapeutic peptide production. Solution-phase synthesis (LPPS) accounts for 30%, primarily used for complex, long-chain peptides and high-purity applications. The hybrid approach represents 15%, combining the advantages of SPPS and LPPS for specialized peptide synthesis needs.

➥ By Product Type, reagents & consumables lead with 45%, reflecting high demand for synthesis resins, solvents, protective groups, and purification kits required for both research and commercial peptide production. Equipment contributes 35%, fueled by adoption of automated synthesizers, high-throughput purification systems, and continuous-flow reactors. Services hold 20%, encompassing contract manufacturing, custom peptide synthesis, and process development offered by CDMOs and specialized peptide providers.

➥ By Application, therapeutic peptides account for 60%, driven by oncology, metabolic disorders, and infectious disease treatment pipelines. Research applications hold 25%, including molecular biology, biomarker studies, and academic investigations. Diagnostics contribute 15%, supported by peptide-based assays, biomarker detection, and diagnostic reagents.

➥ By End-User, pharmaceutical and biotechnology companies dominate with 50%, utilizing peptide synthesis for drug development, clinical trials, and pipeline expansion. CDMOs & CROs account for 30%, providing outsourced synthesis and production services. Academic and research institutes represent 20%, focusing on peptide research, assay development, and preclinical studies.

Regional Insights:

North America dominates the peptide synthesis market with a 35% share (USD 273.0 million in 2023), driven by advanced biopharmaceutical infrastructure, high R&D expenditure, and the presence of key market players such as Bachem, Thermo Fisher Scientific, and GenScript. The U.S. leads the region due to significant adoption of SPPS and LPPS technologies for therapeutic peptide production, peptide-based vaccines, and research applications.

Europe holds a 30% share (USD 234.0 million in 2023), supported by strong pharmaceutical and biotech sectors, regulatory support for peptide therapeutics, and growing investments in automated peptide synthesis equipment. Key markets include Germany, Switzerland, and France, where research initiatives and commercial peptide manufacturing are expanding rapidly.

Asia-Pacific accounts for 25% (USD 195.0 million in 2023), emerging as the fastest-growing region with a projected CAGR above 12% during 2025-2033. Growth is driven by rising healthcare expenditure, increasing prevalence of chronic diseases, expanding biotech research facilities, and adoption of advanced peptide synthesis technologies in countries such as China, Japan, and India.

Latin America, Middle East & Africa (LAMEA) contribute 10% (USD 78.0 million in 2023), with growth supported by emerging pharmaceutical markets, increased R&D investment, and rising demand for peptide therapeutics and diagnostics in countries such as Brazil, Mexico, South Africa, and UAE.

Speak to Our Analyst and Get Customization in the report as per your requirements:-https://www.datamintelligence.com/customize/peptide-synthesis-market?Juli

Market Dynamics:

Drivers
The peptide synthesis market is primarily driven by the growing demand for therapeutic peptides, peptide-based vaccines, and biologics, particularly in oncology, metabolic disorders, and infectious diseases. Increasing R&D investments, expanding peptide pipelines, and rising adoption of solid-phase and solution-phase synthesis technologies are accelerating market growth. Innovations in automated synthesizers, high-throughput purification systems, and continuous-flow processes are enhancing efficiency, scalability, and yield while reducing costs and resource consumption.

Restraints
High capital investment in advanced peptide synthesis equipment, purification systems, and automated platforms can limit adoption, especially among smaller biotech firms or academic institutions. Complex synthesis processes for long-chain or modified peptides, coupled with stringent regulatory requirements, may also hinder rapid market expansion.

Opportunities
Significant opportunities exist in custom peptide synthesis services, contract manufacturing, and hybrid synthesis approaches that combine SPPS and LPPS advantages. Emerging markets in Asia-Pacific, Latin America, and the Middle East offer high growth potential due to increasing healthcare expenditure, rising biotech research activities, and growing adoption of peptide therapeutics. Collaborations between CDMOs, pharmaceutical companies, and research institutes for peptide development and production further expand market opportunities.

Trends
The market is witnessing a shift toward automated, AI-assisted peptide synthesis platforms and continuous-flow solution-phase processes that enhance reproducibility, reduce error rates, and enable large-scale production. There is also increasing focus on high-purity peptides, environmentally sustainable synthesis methods, and integrated workflow solutions. Rising interest in peptide-based diagnostics, precision medicine, and immunotherapies is driving innovation and adoption across research and commercial applications.

Key Developments:

✅ July 2024: BioDuro inaugurated a fully automated solid-phase peptide synthesis (SPPS) scale-up laboratory at its Shanghai Zhangjiang High-tech Park campus in China. This facility enhances the company's peptide synthesis capabilities, enabling efficient and scalable manufacturing to meet growing global demand.

✅ December 2024: Solid Science Plc, a Hungarian biotechnology firm, introduced the RevoPSy instrument, an innovative automated peptide synthesis platform designed to improve throughput, reduce synthesis errors, and streamline workflow for both research and therapeutic peptide production.

Suggestions for Related Report
Peptide Therapeutics Markethttps://www.datamintelligence.com/download-sample/peptide-therapeutics-market?Juli

Oligonucleotide Synthesis Markethttps://www.datamintelligence.com/download-sample/oligonucleotide-synthesis-market?Juli

📌 Request for 2 Days FREE Trial Access: https://www.datamintelligence.com/reports-subscription

☛ Power your decisions with real-time competitor tracking, strategic forecasts, and global investment insights all in one place.

✅ Competitive Landscape

✅ Sustainability Impact Analysis

✅ KOL / Stakeholder Insights

✅ Unmet Needs & Positioning, Pricing & Market Access Snapshots

✅ Market Volatility & Emerging Risks Analysis

✅ Quarterly Industry Report Updated

✅ Live Market & Pricing Trends

✅ Import-Export Data Monitoring

☛ Have a look at our Subscription Dashboard: https://www.youtube.com/watch?v=x5oEiqEqTWg?Juli

Contact Us -
Company Name: DataM Intelligence
Contact Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com

About Us -
DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.

Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.

This release was published on openPR.